A Chinese mRNA COVID vaccine received its first emergency use authorization in Indonesia for people aged 18 years and above, even before approval in its home country China, Reuters reported. Indonesia's food and drug authority (BPOM) granted emergency use authorization to the mRNA COVID vaccine called AWcorna, developed by Walvax...
This week Nature Medicine published the third in a new fortnightly column called The Clinical Pipeline. Our goal is to further strengthen the journal's coverage of translational and clinical research, from bench to bedside, and so each column will analyse a recent clinical trial announcement, preprint, or journal publication (with all the caveats that apply to non-peer reviewed research!)
Floridians aren't rushing to get the updated COVID-19 boosters that were distributed statewide this month. What's happening: A state health report released Friday shows that only 37,000 of Florida's 20 million eligible residents received the new bivalent vaccine, which is intended to target Omicron subvariants, the South Florida Sun-Sentinel reports.
Pfizer (PFE) and BioNTech SE (BNTX) announced they have completed a submission to the European Medicines Agency, or EMA, for a 10-microgram booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children 5 through 11 years of age. "This application for a variation of the marketing authorization to include the Omicron BA.4/BA.5-adapted bivalent vaccine in this age group is supported by safety and immunogenicity data from the companies’ Omicron BA.1-adapted bivalent vaccine, non-clinical and manufacturing data from the companies’ 10-microgram Omicron BA.4/BA.5-adapted bivalent vaccine, and preclinical data from the companies’ Omicron BA.4/BA.5-adapted bivalent vaccine," the companies stated. Reference Link.
Several hedge funds have recently modified their holdings of the business. Invesco Ltd. increased its position in BioNTech by 820.6% during the fourth quarter. Invesco Ltd. now owns 69,212 shares of the company’s stock valued at $17,843,000 after acquiring an additional 61,694 shares during the last quarter. Rockefeller Capital Management L.P. increased its position in BioNTech by 367.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 4,980 shares of the company’s stock valued at $1,283,000 after acquiring an additional 3,915 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in BioNTech during the fourth quarter valued at $316,000. Guggenheim Capital LLC increased its position in BioNTech by 42.8% during the fourth quarter. Guggenheim Capital LLC now owns 21,015 shares of the company’s stock valued at $5,418,000 after acquiring an additional 6,294 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in BioNTech during the fourth quarter valued at $22,867,000. Hedge funds and other institutional investors own 13.77% of the company’s stock.
Merck & Co. struck a deal with Chinese state-owned drugmaker Sinopharm to import and market its antiviral molnupiravir in China, in a tentative sign the country is considering more Covid-19 medicines from overseas developers. Merck and Sinopharm are also evaluating the feasibility of a technological transfer that will facilitate the...
These vaccines target the wild strain as well as the Omicron BA.4/BA.5 variants. Pfizer-BioNTech announced yesterday they had submitted their application for an FDA emergency use authorization (EUA) for their 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age.